Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT552… Read more
Bicycle Therapeutics plc (50BA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.115x
Based on the latest financial reports, Bicycle Therapeutics plc (50BA) has a cash flow conversion efficiency ratio of -0.115x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-71.17 Million) by net assets (€618.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bicycle Therapeutics plc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Bicycle Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Bicycle Therapeutics plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bicycle Therapeutics plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Paringa Resources Limited
PINK:PNGZF
|
0.163x |
|
Garuda Maintenance Facility AeroAsia Tbk PT
JK:GMFI
|
-0.043x |
|
Shengfeng Development Limited Class A Ordinary Shares
NASDAQ:SFWL
|
-0.112x |
|
Promimic AB
ST:PRO
|
-0.017x |
|
HeveaBoard Bhd
KLSE:5095
|
-0.003x |
|
Texmo Pipes and Products Limited
NSE:TEXMOPIPES
|
-0.079x |
|
Beauty Skin Corp.
KQ:406820
|
-0.066x |
|
SY PUBLIC UTIL -H- (SH3.SG)
STU:SH3
|
-0.353x |
Annual Cash Flow Conversion Efficiency for Bicycle Therapeutics plc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Bicycle Therapeutics plc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €793.06 Million | €-164.72 Million | -0.208x | -76.51% |
| 2023-12-31 | €370.93 Million | €-43.65 Million | -0.118x | +63.00% |
| 2022-12-31 | €270.78 Million | €-86.11 Million | -0.318x | -644.30% |
| 2021-12-31 | €346.25 Million | €-14.79 Million | -0.043x | +77.07% |
| 2020-12-31 | €95.46 Million | €-17.79 Million | -0.186x | +39.30% |
| 2019-12-31 | €93.20 Million | €-28.61 Million | -0.307x | -182.21% |
| 2018-12-31 | €-69.83 Million | €-26.08 Million | 0.373x | -- |